De novo <scp>CD</scp>5+ diffuse large <scp>B</scp>‐cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort
Lapo Alinari(University of Milan), Kristie A. Blum(Emory University), Jonathon B. Cohen(Emory University), Gerard Lozanski(The Ohio State University), Alejandro A. Gru(University of Virginia), Peter Martin(Northwestern University), Girish Venkataraman, Eunhye Oak(Washington University in St. Louis), Carl Quinion(The Ohio State University Wexner Medical Center), Friederike Kreisel(Saint Louis University), Andrew M. Evens(Rutgers, The State University of New Jersey), Arletta Lozanski(The Ohio State University), Timothy S. Fenske(Medical College of Wisconsin), Jacqueline N. Poston(University of Vermont), Arun Singavi(Medical College of Wisconsin), Ying Huang(Linyi University), Hana I. Lim(Cornell University), Stephanie B. Matthews(University of North Carolina at Chapel Hill), Jeremy S. Abramson(Massachusetts General Hospital), Steven I. Park(University of North Carolina at Chapel Hill), Zeina Al‐Mansour(University of Massachusetts Chan Medical School)
Cited by 49
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k